Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). PT Kalbe Farma Tbk's share price for the quarter that ended in Mar. 2026 was €0.054. PT Kalbe Farma Tbk's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 45,249 Mil. Therefore, PT Kalbe Farma Tbk's market cap for the quarter that ended in Mar. 2026 was €2,443 Mil.
PT Kalbe Farma Tbk's quarterly market cap
declined
from Sep. 2025 (€2,356 Mil) to Dec. 2025 (€1,381 Mil) but then
increased
from Dec. 2025 (€1,381 Mil) to Mar. 2026 (€2,443 Mil).
PT Kalbe Farma Tbk's annual market cap
declined
from Dec. 2023 (€3,585 Mil) to Dec. 2024 (€2,987 Mil) and
declined
from Dec. 2024 (€2,987 Mil) to Dec. 2025 (€1,381 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. PT Kalbe Farma Tbk's Enterprise Value for Today is €1,609 Mil.
PT Kalbe Farma Tbk (FRA:LCLA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
PT Kalbe Farma Tbk Market Cap Related Terms
PT Kalbe Farma Tbk Market Cap Historical Data
* Premium members only.
The historical data trend for PT Kalbe Farma Tbk's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, PT Kalbe Farma Tbk's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kalbe Farma Tbk Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Kalbe Farma Tbk's Market Cap distribution charts can be found below:
* The bar in red indicates where PT Kalbe Farma Tbk's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
PT Kalbe Farma Tbk's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Kalbe Farma Tbk (FRA:LCLA) has a Market Cap of €1,747 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on PT Kalbe Farma Tbk and its competitors. According to the industry distribution chart, PT Kalbe Farma Tbk ranks #152 out of 1020 companies in the Drug Manufacturers industry, placing it in the top 14.9%.
Is PT Kalbe Farma Tbk's Market Cap too high?
PT Kalbe Farma Tbk's current Market Cap is €1,747 Mil. Based on the distribution chart, PT Kalbe Farma Tbk ranks #152 out of 1020 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PT Kalbe Farma Tbk has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kalbe Farma Tbk's Market Cap compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, PT Kalbe Farma Tbk ranks #152 out of 1020 companies for Market Cap. This places PT Kalbe Farma Tbk in the top 15% of its industry — outperforming the majority of peers. The industry median Market Cap is 204.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 204.29, based on 1,020 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on PT Kalbe Farma Tbk and its competitors. For the Drug Manufacturers industry, the median Market Cap is 204.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kalbe Farma Tbk's current Market Cap is €1,747 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kalbe Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk (FRA:LCLA) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.07, compared to a current price of €0.03 — trading 52.1% below its estimated fair value. The current Market Cap is €1,747 Mil. PT Kalbe Farma Tbk's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For PT Kalbe Farma Tbk (FRA:LCLA), the current Market Cap is €1,747 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kalbe Farma Tbk (FRA:LCLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk stock appears to be undervalued.
The current stock price of €0.03 is trading 52.1% below its estimated GF Value™ of €0.07.
GuruFocus considers PT Kalbe Farma Tbk to be Significantly Undervalued.
Key valuation signals for FRA:LCLA:
Market Cap: €1,747 Mil
GF Value™: €0.07 vs. price of €0.03 (52.1% below fair value)
No single metric tells the full story. See the FRA:LCLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
77GF Score
Get the complete analysis for FRA:LCLA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LCLA has been successfully added to your 
